Methods of treating cognitive disorders by inhibition of gpr12

Abstract

The present invention provides methods for screening a pharmaceutical agent for its ability to modulate long term memory formation, performance of a hippocampal-dependent cognitive task or Gpr12 function. The present invention also provides methods for modulating long term memory formation or performance of a hippocampal-dependent cognitive task by modulating Gpr12-dependent protein expression. The present invention further provides methods for treating a defect in long term memory formation by inhibiting Gpr12 function and methods for treating a defect in performance of a hippocampal-dependent cognitive task by inhibiting Gpr12 function.

1 - 29 . (canceled) 
     
     
         30 . A method comprising:
 (a) administering to a mammal an effective amount of a pharmaceutical agent which inhibits Gpr12 activity in the mammal;   (b) providing training to said mammal under conditions sufficient to produce an improvement in performance by the mammal of a cognitive task;   (c) producing a long-lasting performance gain in said mammal relative to the performance of said cognitive task achieved by training alone.   
     
     
         31 . The method of  claim 30 , wherein the mammal is an adult mammal. 
     
     
         32 . The method of  claim 30 , wherein the mammal is a human. 
     
     
         33 . The method of  claim 30 , wherein said administering results in enhancement in long term memory formation. 
     
     
         34 . The method of  claim 33 , wherein said mammal shows normal short-term memory relative to animals that have not been administered the pharmaceutical agent. 
     
     
         35 . The method of  claim 33 , further comprising detecting said enhancement in said long term memory formation. 
     
     
         36 . The method of  claim 35 . wherein said detecting of said enhancement is the detection of enhancement of a hippocampal-dependent cognitive task. 
     
     
         37 . The method of  claim 35 , wherein said detecting of said enhancement is the detection of enhancement of an amygdala-dependent cognitive task. 
     
     
         38 . The method of  claim 35 , wherein said detecting of said enhancement is the detection of enhancement of a hippocampal-dependent cognitive task and an amygdala-dependent cognitive task. 
     
     
         39 . The method of  claim 30 , wherein the inhibition of Gpr12 activity comprises inhibition of Gpr12 protein expression in the mammal. 
     
     
         40 . The method of  claim 30 , wherein the training comprises multiple training sessions. 
     
     
         41 . The method of  claim 30 , wherein the training comprises spaced training sessions. 
     
     
         42 . The method of  claim 30 , wherein said pharmaceutical agent is administered before and/or during each training session. 
     
     
         43 . A method comprising:
 (a) introducing a pharmaceutical agent of interest into host cells expressing a Gpr12 protein; and   (b) determining Gpr12 function, wherein a decrease in the Gpr12 function determined in (b) compared to the Gpr12 function of host cells of (a) to which said pharmaceutical agent has not been administered identifies the pharmaceutical agent as a candidate drug capable of enhancing long-term memory formation in a mammal.   
     
     
         44 . The method of  claim 43  wherein said mammals are adult mammals. 
     
     
         45 . The method of  claim 43  wherein said mammals are humans. 
     
     
         46 . The method of  claim 43  wherein said long term memory formation is hippocampus-dependent long term memory formation. 
     
     
         47 . The method of  claim 43  wherein said long term memory formation is amygdala-dependent long term memory formation. 
     
     
         48 . The method of  claim 43  wherein said long term memory formation is hippocampus-dependent and amygdala-dependent long term memory formation. 
     
     
         49 . The method of  claim 43  wherein the inhibition of Gpr12 activity comprises inhibition of Gpr12 protein expression in the mammal. 
     
     
         50 . The method of  claim 43  wherein said pharmaceutical agent comprises an effective amount of a Gpr12 siRNA molecule, a biologically active Gpr12 antisense fragment, or a small molecule.